BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa, fo...
AB-BIOBETTER, led by Bio-Sourcing, to pioneer development of new oral formulation of adalimumab for inflammatory bowel diseases; offering patient...
Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, is significantly expandin...
Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clini...
YGION Biomedical GmbH, a company dedicated to developing individualized neoantigen-based cancer vaccines, today announced the completion of a Series A fina...
German Chancellor Olaf Scholz emphasizes significance for Germany as research location at cornerstone laying ceremony Research center to accelerate biop...
Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical de...
EXO Biologics, a clinical-stage biotech and a pioneer in developing exosome-based therapies, announces the successful securing of a t...
Under Narasimhan's leadership, the company sees significant sales and profit growth across major products, prompting an upward revision of the full-year 20...
SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for microbial gene the...
Johnson & Johnson announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to...
The facilities, located in Solna, Stängnäs, Höganäs, Karlskoga, and Uppsala OTC Development in Sweden, Pessac in France...
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company specializing in allosteric modulation-based drug development,...
“The acquisition of CymaBay brings us a potential best-in-disease therapy that could transform the treatment landscape for people wit...
© 2025 Biopharma Boardroom. All Rights Reserved.
